ScoreWhy is Bolt Biotherapeutics, Inc. ?
1
- OPERATING CASH FLOW(Y) Highest at USD -47.12 MM
- NET SALES(HY) Higher at USD 3.97 MM
- OPERATING PROFIT(Q) Highest at USD -7.41 MM
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -50.17%, its profits have risen by 32.7%
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -5.59% over the previous quarter and currently hold 23.29% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 11.87% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -50.17% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Bolt Biotherapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Bolt Biotherapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Bolt Biotherapeutics, Inc.
-41.25%
0.27
1809.74%
S&P 500
16.08%
0.62
19.30%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
42.62%
EBIT Growth (5y)
-1.44%
EBIT to Interest (avg)
-76.02
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.80
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
56.76%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.27
EV to EBIT
0.48
EV to EBITDA
0.49
EV to Capital Employed
-10.10
EV to Sales
-4.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-129.07%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -47.12 MM
NET SALES(HY)
Higher at USD 3.97 MM
OPERATING PROFIT(Q)
Highest at USD -7.41 MM
PRE-TAX PROFIT(Q)
Highest at USD -7.14 MM
NET PROFIT(Q)
Highest at USD -7.14 MM
RAW MATERIAL COST(Y)
Fallen by -41.68% (YoY
EPS(Q)
Highest at USD -3.72
-6What is not working for the Company
NET SALES(9M)
At USD 5.2 MM has Grown at -32.44%
DEBT-EQUITY RATIO
(HY)
Highest at -28.36 %
Here's what is working for Bolt Biotherapeutics, Inc.
Net Sales
At USD 3.97 MM has Grown at 64.45%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -47.12 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD -7.41 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -7.14 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -7.14 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Higher at USD 3.97 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Pre-Tax Profit
At USD -7.14 MM has Grown at 52.93%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -7.14 MM has Grown at 52.93%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -3.72
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -41.68% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Bolt Biotherapeutics, Inc.
Debt-Equity Ratio
Highest at -28.36 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
